High-Tech Surgery, Unequal Access: Fighting Inequity in Kidney Cancer Treatment

Even as robotic surgery and partial nephrectomy redefine kidney cancer treatment, the benefits are not reaching all patients equally. A new study published in JU Open Plus in March 2026, led by Pablo E. Puente and a distinguished team from the University of Miami, reveals persistent racial and ethnic disparities in the use of kidney-preserving and robotic-assisted surgeries for renal cell carcinoma. By analyzing a massive cohort of 122,920 patients from the National Cancer Database between 2010 and 2019, the research highlights a systemic access gap that remains significant even after adjusting for insurance type, income, and education levels.

Partial nephrectomy is the clinical gold standard for small renal masses because it maintains oncologic control while preserving vital kidney function, yet the study found that for these early-stage cT1a tumors, non-Hispanic Black patients had 29% lower odds and Hispanic patients faced 20% lower odds of receiving this kidney-sparing approach compared to White patients. These inequities extended into more complex cases, though the data revealed a unique divergence for Black patients. While Hispanic patients remained less likely to receive a partial nephrectomy across nearly all stages, Black patients actually showed higher odds of receiving kidney-sparing surgery for larger cT1b and cT2 tumors. Researchers suggest this may be driven by clinical necessity, as Black populations often have a higher baseline risk for chronic kidney disease, forcing surgeons to attempt complex nephron-sparing surgeries to avoid total renal failure.

The study also tracked the broader robotic revolution and found that non-Hispanic White patients had the highest utilization rates of robotic-assisted surgery across every single tumor stage. In contrast, Black patients were significantly less likely to access robotic platforms for all stages of localized kidney cancer, and Hispanic patients faced significantly lower odds of robotic access for cT1a and cT1b masses. These disparities are rooted deeply in the business of surgery rather than just clinical choice. Systemic factors such as referral patterns and the concentration of high-end technology in elite academic centers mean that vulnerable populations are more likely to be treated at lower-volume community centers that may lack the specialized instrumentation or robotic platforms required for complex cases.

The consequences of this gap are tangible, leading to a higher risk of postoperative complications, longer recovery times, and the long-term health burden of chronic kidney disease for the populations already most vulnerable. The findings from Puente and colleagues make it clear that the next revolution in surgery is not just about designing more expensive technology, but about democratizing access. To close these gaps, the industry must focus on empowering community-level cancer programs with the same high-quality, cost-effective tools found in major research hubs. Only by breaking down these institutional barriers can we ensure that every patient, regardless of race or geography, benefits from the safest and most effective surgical care available today.

Read the detailed research article here: Racial and Ethnic Disparities in the Utilization of Partial Nephrectomy and Robotic Surgery for Renal Cell Carcinoma

Reference: Puente PE, Freitas PFS, Williams AD, Gonzalgo MR, Khandekar A, Nahar B, Punnen S, Parekh DJ, Gonzalgo ML. Racial and Ethnic Disparities in the Utilization of Partial Nephrectomy and Robotic Surgery for Renal Cell Carcinoma. JU Open Plus. 2026;4(3):e00027.

Experience a smarter way to source endoscopy equipment—all in one place.

✔ Wide selection of trusted endoscopy brands

✔ Competitive pricing without compromising quality

✔ Fast, reliable access to the tools you need—when you need them

👉 Explore how EndoPro® 3D can transform your surgical technique.